转移性激素敏感性前列腺癌雄激素剥夺治疗后骨及淋巴结闪烁现象:18F-PSMA PET/CT示前列腺特异性抗原降至0.7 ng/mL
72岁前列腺癌患者初始分期18F-DCFPyL PET/CT示前列腺特异性膜抗原(PSMA)阳性寡转移,前列腺特异性抗原10.0 ng/mL、睾酮381 ng/dL。雄激素剥夺治疗联合阿比特龙治疗6周后复查,原发前列腺病灶PSMA摄取减低,但骨及淋巴结转移灶摄取增高,同时前列腺特异性抗原降至0.7 ng/mL、睾酮<3 ng/dL。本病例展示了激素敏感性转移性骨及淋巴结闪烁现象在18F-PSMA PET/CT上的表现。
要点
- 激素敏感性转移性前列腺癌雄激素剥夺治疗后6周可出现骨及淋巴结PSMA摄取增高。
- 该闪烁现象可伴随前列腺特异性抗原下降(10.0 ng/mL降至0.7 ng/mL)及睾酮抑制(<3 ng/dL)。
- 18F-PSMA PET/CT上原发灶摄取减低而转移灶摄取增高,需识别为闪烁现象而非进展。
核心结论
- 本病例说明激素敏感性转移性前列腺癌在接受雄激素剥夺治疗联合阿比特龙后,18F-PSMA PET/CT上可表现为骨及淋巴结闪烁现象。
研究设计与样本
- 单例病例报告:72岁前列腺癌患者,初始分期行18F-DCFPyL PET/CT,治疗6周后复查18F-DCFPyL PET/CT。
主要发现
- 初始分期18F-DCFPyL PET/CT示PSMA阳性寡转移,前列腺特异性抗原10.0 ng/mL,睾酮381 ng/dL。
- 雄激素剥夺治疗联合阿比特龙治疗6周后复查18F-DCFPyL PET/CT,原发前列腺病灶PSMA摄取减低,骨及淋巴结转移灶摄取增高。
- 同期前列腺特异性抗原降至0.7 ng/mL,睾酮降至<3 ng/dL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 72-year-old man with prostate cancer was found to have prostate-specific membrane antigen (PSMA)-avid oligometastasis on initial staging with 18F-DCFPyL PET/CT. Meanwhile, his prostate-specific antigen was 10.0 ng/mL, and testosterone level was 381 ng/dL. Six weeks after initiation of treatment on androgen deprivation therapy plus abiraterone, his restaging 18F-DCFPyL PET/CT showed decreased PSMA uptake in primary prostate lesion, but increased uptake in bone and lymph node metastases, whereas his prostate-specific antigen decreased to 0.7 ng/mL, and testosterone level was <3 ng/dL. This case illustrates hormone-sensitive metastatic bone and lymph node flare on 18F-PSMA PET/CT.
引用
- Lu Y. Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL. Clin Nucl Med. 2022. PMID: 35175941. doi:10.1097/RLU.0000000000004107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。